Latest Conference Articles

Flash CGM Increases Time in Range for T2D Patients on Noninsulin Therapies Not at Goal HbA1c

Flash CGM Increases Time in Range for T2D Patients on Noninsulin Therapies Not at Goal HbA1c

June 10th 2022

ADA

ADA 2022: Use of flash continuous glucose monitoring in T2D patients not on insulin also reduced HbA1c and glycemic variability, a new study finds.

Continuous Glucose Monitoring Linked to Better Glycemic Control, Reduced Hospitalizations in Study of Veterans Health Administration Data

Continuous Glucose Monitoring Linked to Better Glycemic Control, Reduced Hospitalizations in Study of Veterans Health Administration Data

June 8th 2022

ADA

ADA 2022: Large national study found that CGM use had a positive effect on glycemic control and acute complications in T2D in the Veterans Health Administration.

Glycemic Variability with Tirzepatide Significantly Lower vs Degludec as Assessed by CGM

Glycemic Variability with Tirzepatide Significantly Lower vs Degludec as Assessed by CGM

June 8th 2022

ADA

ADA 2022. Tirzepatide was associated with significantly greater TIR, many fewer episodes of hypoglycemia, and less glycemic excursion vs insulin degludec in SURPASS-3 CGM.

Poorly Controlled T2D Improves with Initiation of rtCGM in Primary Care

Poorly Controlled T2D Improves with Initiation of rtCGM in Primary Care

June 8th 2022

ADA

ADA 2022: Primary care patients with T2D and HbA1c >7.5% achieved as much as a 1.5% drop in HbA1c after initiating real time continuous glucose monitoring.

Study: AI-powered Intervention Led to Highest Reported Rate of T2D Remission to Date

Study: AI-powered Intervention Led to Highest Reported Rate of T2D Remission to Date

June 7th 2022

ADA

ADA 2022: Patients with T2D who received a treatment intervention powered by artificial intelligence achieved a remission rate of more than 80%.

Semaglutide 2.4 mg Reduces 10-year Risk of Type 2 Diabetes in Patients with Overweight,  Obesity

Semaglutide 2.4 mg Reduces 10-year Risk of Type 2 Diabetes in Patients with Overweight, Obesity

June 7th 2022

ADA

ADA 2022: Reduction in risk of progression to type 2 diabetes of 60% was seen in STEP program clinical trial participants with overweight or obesity.

Dulaglutide Improves HbA1c for Youth with Type 2 Diabetes without Change in BMI

Dulaglutide Improves HbA1c for Youth with Type 2 Diabetes without Change in BMI

June 7th 2022

ADA

ADA 2022: "Breakthrough" findings may help to address the unmet need for additional treatment options for young patients with type 2 diabetes.

Oral Semaglutide in Real-world Study Found Highly Effective for Uncontrolled HbA1c

Oral Semaglutide in Real-world Study Found Highly Effective for Uncontrolled HbA1c

June 7th 2022

ADA

ADA 2022: Oral semaglutide may be particularly effective for T2D patients with HbA1c ≥9% and prescribed more frequently for these patients by primary care clinicians.

Kidney Outcomes with Tirzepatide in T2D: Hiddo Heerspink, PhD, PharmD Highlights SURPASS-4 Analysis

Kidney Outcomes with Tirzepatide in T2D: Hiddo Heerspink, PhD, PharmD Highlights SURPASS-4 Analysis

June 6th 2022

ADA

ADA 2022: Professor Hiddo Heerspink led the prespecified SURPASS-4 analysis that found tirzepatide associated with a 41% reduction in risk of a composite renal outcome.

Empagliflozin More Effective to Reduce Risk of Heart Failure Hospitalization vs DPP-4 Inhibitors, GLP-1 Receptor Agonists

Empagliflozin More Effective to Reduce Risk of Heart Failure Hospitalization vs DPP-4 Inhibitors, GLP-1 Receptor Agonists

June 6th 2022

ADA

ADA 2022: In a real-world study of nearly half a million adults with T2D followed for 5 years, the SGLT-2 inhibitor surpassed both other classes used in routine clinical care.